Phaseline

Companies › Foghorn Therapeutics

Foghorn Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FHD-286–Phase 1Advanced Hematologic Malignancy; Small Cell Lung Cancer; Acute Myeloid LeukemiaJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04891757FHD-286Phase 1Advanced Hematologic MalignancyOncologyJun 2027
NCT07551635FHD-286Phase 2Small Cell Lung CancerOncologyJan 2028
NCT07283094FHD-286Phase 1Acute Myeloid LeukemiaOncologyMay 2028

From the company's SEC filings

Cash of $80m on 2026-09-30; operating cash outflow about $82m a year; runway about 12 months at that burn, to Sep 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.